glofitamab
roche
['lymsm', 'glofitamab', 'lymphoma']
#eha2022 | crs incidence and severity improved significantly with mandatory dex, especially after 1st dose.
further information on glofitamab's safety profile #lymphoma #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm